期刊文献+

非炎症性前部缺血性视神经病变患者经复方樟柳碱治疗前后血浆内皮素1浓度的测定 被引量:1

The Determination of Plasma Endothelin-1 Level in Nonarteritic Anterior Ischemic Optic Neuropathy Patients with Compound Anisodine before and after Treatment
下载PDF
导出
摘要 目的测定非动脉炎性前部缺血性视神经病变(NAION)患者在复方樟柳碱治疗前后血浆中内皮素1(ET-1)的浓度,探讨其变化规律。方法NAION患者39例,给予复方樟柳碱2mL颞浅动脉旁注射,共治疗21d,所有患者按治疗效果分为三组(A组为治愈,B组为显效或有效,C组为无效),分别通过放射免疫法(RIA)测定治疗前后血浆ET-1浓度。结果各组治疗前的血浆ET-1浓度,A、B组高于C组,其差别有显著性意义(tAC=4.67,P<0.05;t.BC=4.03,P<0.05)),而A、B组之间差别无显著性意义(tA.B=1.34,P>0.1)。各组治疗后的血浆ET-1浓度,其分布规律同治疗前有统计学意义(tAC=4.13,P<0.05;tBC=3.89,P<0.05;tAB=0.67,P>0.1);各组治疗后的血浆ET-1浓度较治疗前均有所下降,A组、B组其治疗前后的浓度差别有显著性意义(FA=4.78,P<0.05;FB=4.32,P<0.05),C组治疗前后的浓度差别无显著性意义(FC=0.78,P>0.1)。结论复方樟柳碱对NAION患者的治疗效果,可能与血浆ET-1水平有关。 Objective To measured the level of plasma endothelin-1 (ET-1)in patients with nonarteritic anterior ischemic optic neuropathy(NAION) before and after treatment by compound anisodine and to explore its changes rule. Methods 39 patients with NAION were treated by compound anisodine which was injected subcutaneously around superficial temporal artery once a day for 21days. All the patients were divided into three groups according to the results after treatment(groups A, CURE; group B, efficacy; group C, no efficacy). The plasma levels of ET-1 in 39 cases before and after treatment were measured by radioimmuoassay(RIA). Results The plasma levels of ET-1 before and after treatment in group A and group B were significantly higher than those in group C. There was no significantly difference between group A and group B.The plasma levels of ET-1 in patients after treatment were obviously lower than those before treatment. There was significantly difference in group A and group B but not in group C. Conclusion The efficiency of compound anisodine on patients with NAION may result in the plasma levels of ET-1.
作者 陈继远
出处 《中国医药指南》 2009年第11期29-30,共2页 Guide of China Medicine
关键词 缺血性视神经病变 复方樟柳碱 内皮素1 Ischemic optic neuropathy Compound anisondine Endothelin-1
  • 相关文献

参考文献4

二级参考文献17

  • 1滕学龙.复方樟柳碱治疗前部缺血性视神经病变的临床观察[J].国际眼科杂志,2004,4(4):778-778. 被引量:35
  • 2王润生.前部缺血性视神经病变发病机理探讨[J].中国实用眼科杂志,1995,13(12):754-756. 被引量:20
  • 3Prasanna G, Narayan S, Krishnamoorthy RR, et al. Eyeing endothelins: a cellular perspective. Mol Cell Biochem, 2003,253:71-88.
  • 4Hayreh SS. Blood supply of the optic nerve head.Ophthalmologica, 1996,210: 285-295.
  • 5Cioffi GA, Sullivan P. The effect of chronic ischemia on the primate optic nerve. Eur J Ophthalmol, 1999,9 Suppl 1:34-36.
  • 6Burde RM. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol, 1993:759-764.
  • 7Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology,1999,106: 739-742.
  • 8Hayreh SS,Zimmerman MB, Podhajsky P,et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthamol, 1994,117: 603-624.
  • 9Landun K, WinterKorn JMS,Mailloux LU,et al. 24-hours blood pressure monitoring in patients with anterior ischemic optic neuropathy. Arch Ophthalmol, 1996,114: 570-575.
  • 10劳远锈 赖宗白.视神经病[A].见:张承芬 主编.眼底病学[C].北京:人民卫生出版社,1998.487-490.

共引文献58

同被引文献30

  • 1陈艳虹,吴联群.复方樟柳碱治疗原发性开角型青光眼疗效的临床研究[J].浙江大学学报(医学版),2011,40(6):659-662. 被引量:12
  • 2周贤刚,钟渠,许明德.复方樟柳碱注射液治疗缺血性视神经病变的系统评价[J].临床眼科杂志,2006,14(3):229-234. 被引量:22
  • 3Kass MA,Heuer DK,Higginbotham E J, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open- angle glaucoma [ J ]. Arch Ophthalmol, 2002,120 ( 6 ) : 701 - 713. doi : 10. lO01/archopht. 120.6. 701.
  • 4Sommer A. Intraocular pressure and glaucoma[ J]. Am J Ophthalmol, 1989,107(2) : 186-188. doi:10. 1016/0002-9394(89)90221-3.
  • 5Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma[ J ]. Am J Ophthalmol, 1998,126 ( 4 ) : 498 - 505. doi : 10. 1016/s0002-9394 ( 98 ) 00272-4.
  • 6Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial[J]. Arch Ophthalmol, 2002,120 ( 10 ) : 1268 - 1279. doi:10. 1001/archopht. 120.10. 1268.
  • 7Musch DC,Gillespie BW, Lichter PR, et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors [ J ]. Ophthalmology, 2009,116 ( 2 ) : 200-207. doi: 10. lO16/sO084-392x( 10 )79332-1.
  • 8Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma[ J ]. Prog Retin Eye Res, 2002,21 ( 4 ) : 359 - 393. doi: 10. 1016/s1350- 9462(02)00008-3.
  • 9Hayreb SS. Prevalent misconceptions about acute retinal vascular occlusive disorders [ J ]. Prog Retin Eye Res, 2005,24 ( 4 ) : 493 - 519. doi:10, lO16/j, preteyeres. 2004.12. 001.
  • 10Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy[J]. Prog Retin Eye Res,2007,26 (3) : 205 -238. doi : 10. 1016/ i. preteveres. 2007.01. 004.

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部